SciSparc-Clearmind Secure European Patent for Psychedelic Therapy for Cocaine Addiction

TEL AVIV, Israel, May 12, 2025 – SciSparc Ltd. (Nasdaq: SPRC), a company specializing in clinical-stage pharmaceuticals, has announced a significant milestone in its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). Their joint efforts have resulted in the European Patent Office publishing a new patent application. This patent concerns a novel treatment method that combines Clearmind's compound, 5-methoxy-2-aminoindane (MEAI), with SciSparc's Palmitoylethanolamide to address cocaine addiction.

The patent application stems from preclinical trials executed by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Israel. These trials showed promising results, where animals treated with MEAI displayed a notable decrease in cravings induced by cocaine. Subsequent investigations aimed to determine whether the effects of MEAI extended to natural reward systems, which are crucial for survival across species. The findings were positive, indicating that while MEAI diminished cocaine-seeking behaviors, it did not affect the animals' responses to natural rewards like sucrose. This suggests that MEAI targets drug-seeking impulses without disrupting natural reward mechanisms.

This publication adds to a series of patent applications by the SciSparc-Clearmind partnership, which have already been lodged in the United States and other global jurisdictions.

SciSparc Ltd. is a clinical-stage pharmaceutical entity led by a seasoned team of executives and researchers. The company's mission is to develop a portfolio of technologies focused on cannabinoid-based pharmaceuticals. Currently, SciSparc is advancing several drug development programs, which include SCI-110 for treating Tourette Syndrome and Alzheimer's-related agitation, and SCI-210 for autism and status epilepticus. Additionally, SciSparc holds a controlling interest in a subsidiary dedicated to selling hemp seed oil products on Amazon.com.

Clearmind Medicine Inc. operates as a clinical-stage biotech firm that leverages psychedelic compounds to create new therapeutics aimed at tackling prevalent and underserved medical issues, such as alcohol use disorder. Clearmind's primary mission involves researching and developing psychedelics-derived compounds with the potential to be commercialized as regulated medications, foods, or supplements. The company's intellectual property portfolio currently consists of 19 patent families, which include 31 granted patents.

This collaborative effort marks a significant step forward in developing innovative treatments for addiction, potentially offering new hope to those struggling with cocaine addiction and other related disorders. The successful publication of the European patent application is a testament to the promising nature of their research and underscores the potential impact of their combined therapies on global health challenges.